Tocagen Inc (26)

Browse by Contract Category

Contracts

Form of Change in Control and Severance Agreement (Filed With SEC on November 14, 2022)
Offer Letter by and between the Company and Hubert Chen, M.D., dated May 31, 2022 (Filed With SEC on August 15, 2022)
Preferred Stock Rights Agreement, dated as of July 12, 2022, by and between Forte Biosciences, Inc. and Computershare Trust Company, N.A., as rights agent (Filed With SEC on July 12, 2022)
At Market Issuance Sales Agreement between the Company and Ladenburg Thalmann & Co. Inc (Filed With SEC on April 1, 2022)
Amendment No. 2 to License Agreement by and between Forte Subsidiary, Inc. and the U.S. Department of Health and Human Services, as represented by the National Institute of... (Filed With SEC on August 10, 2020)
Agreement for Termination of Lease and Voluntary Surrender of Premises, dated June 10, 2020, by and between Tocagen, Inc. and ARE-SD Region No. 61, LLC (Filed With SEC on June 15, 2020)
Agreement and Plan of Merger and Reorganization, dated February 19, 2020, by and among the Company, Merger Sub and Forte (Filed With SEC on February 20, 2020)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 15, 2022)
Forte Biosciences, Inc. 2021 Equity Incentive Plan (Filed With SEC on March 31, 2022)
Underwriting Agreement, dated October 29, 2020 (Filed With SEC on October 29, 2020)
At Market Issuance Sales Agreement between the Company and Ladenburg Thalmann & Co. Inc (Filed With SEC on September 4, 2020)
Form of Warrant to Purchase Common Stock of the Registrant issued on June 15, 2020 (Filed With SEC on August 10, 2020)
Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Martin J. Duvall (Filed With SEC on February 27, 2020)
Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Douglas Jolly, Ph.D (Filed With SEC on February 27, 2020)
Form of Restricted Stock Unit Grant Notice and Agreement (Filed With SEC on February 27, 2020)
First Amendment to Lease Agreement, dated December 16, 2019, by and between the Registrant and AP3-SD1 Campus Point LLC (Filed With SEC on February 27, 2020)
Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Fairooz Kabbinavar M.D (Filed With SEC on February 27, 2020)
Description of Common Stock (Filed With SEC on February 27, 2020)
Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Mark Foletta (Filed With SEC on February 27, 2020)
Form of Forte Support Agreement, dated February 19, 2020, by and between the Company and each of the parties named in each agreement therein (Filed With SEC on February 20, 2020)
Form of Lock-Up Agreement, dated February 19, 2020, by each of the parties named in each agreement therein (Filed With SEC on February 20, 2020)
Form of Company Support Agreement, dated February 19, 2020, by and between Forte and each of the parties named in each agreement therein (Filed With SEC on February 20, 2020)
Consent and Second Amendment to Amended and Restated Loan and Security Agreement, dated October 31, 2019, by and among the Registrant, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 12, 2019)
Executive Employment Agreement, dated April 8, 2019, by and between the Registrant and Harry E. Gruber, M.D (Filed With SEC on August 8, 2019)
Executive Employment Agreement, dated February 26, 2019, by and between the Registrant and Fairooz Kabbinavar M.D (Filed With SEC on August 8, 2019)
Tocagen Inc. 2017 Equity Incentive Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on February 27, 2019)